The in vitro treatment of primary B-CLL cells with the activator of p53 Nutlin-3 induced the transcription of p53 target genes, without significant differences between the B-CLL without mutations and those harboring either ATM or NOTCH1 mutations. The gene discussed is NOTCH1; the disease is B-cell chronic lymphocytic leukemia.